vs
California Resources Corp（CRC）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
California Resources Corp的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.6倍（$119.0M vs $75.5M），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-32.0M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -46.3%）
加州资源集团是一家美国能源企业，主要在加州开展油气勘探业务。公司注册地为特拉华州，总部位于加州长滩，所持有的加州矿产地块面积是该州私有主体中的最高水平。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CRC vs PBYI — 直观对比
营收规模更大
CRC
是对方的1.6倍
$75.5M
自由现金流更多
PBYI
多$46.4M
$-32.0M
两年增速更快
PBYI
近两年复合增速
-46.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $119.0M | $75.5M |
| 净利润 | — | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | -597.5% | 22.7% |
| 净利率 | — | — |
| 营收同比 | — | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-8.02 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRCPBYI
| Q1 26 | $119.0M | — | ||
| Q4 25 | $679.0M | $75.5M | ||
| Q3 25 | $715.0M | $54.5M | ||
| Q2 25 | $702.0M | $52.4M | ||
| Q1 25 | $814.0M | $46.0M | ||
| Q4 24 | $826.0M | $59.1M | ||
| Q3 24 | $870.0M | $80.5M | ||
| Q2 24 | $412.0M | $47.1M |
净利润CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | $12.0M | — | ||
| Q3 25 | $64.0M | $8.8M | ||
| Q2 25 | $172.0M | $5.9M | ||
| Q1 25 | $115.0M | $3.0M | ||
| Q4 24 | $33.0M | — | ||
| Q3 24 | $345.0M | $20.3M | ||
| Q2 24 | $8.0M | $-4.5M |
毛利率CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
营业利润率CRCPBYI
| Q1 26 | -597.5% | — | ||
| Q4 25 | 6.9% | 22.7% | ||
| Q3 25 | 13.7% | 17.6% | ||
| Q2 25 | 38.0% | 12.7% | ||
| Q1 25 | 22.9% | 8.7% | ||
| Q4 24 | 8.2% | 22.6% | ||
| Q3 24 | 59.5% | 27.4% | ||
| Q2 24 | 9.2% | -4.6% |
净利率CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 9.0% | 16.2% | ||
| Q2 25 | 24.5% | 11.2% | ||
| Q1 25 | 14.1% | 6.5% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 39.7% | 25.2% | ||
| Q2 24 | 1.9% | -9.6% |
每股收益（稀释后）CRCPBYI
| Q1 26 | $-8.02 | — | ||
| Q4 25 | $0.21 | $0.26 | ||
| Q3 25 | $0.76 | $0.17 | ||
| Q2 25 | $1.92 | $0.12 | ||
| Q1 25 | $1.26 | $0.06 | ||
| Q4 24 | $0.87 | $0.40 | ||
| Q3 24 | $3.78 | $0.41 | ||
| Q2 24 | $0.11 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $2.9B | $130.3M |
| 总资产 | — | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | $132.0M | $97.5M | ||
| Q3 25 | $196.0M | $94.4M | ||
| Q2 25 | $72.0M | $96.0M | ||
| Q1 25 | $214.0M | $93.2M | ||
| Q4 24 | $372.0M | $101.0M | ||
| Q3 24 | $241.0M | $96.7M | ||
| Q2 24 | $1.0B | $96.8M |
总债务CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | $1.0B | $34.0M | ||
| Q2 25 | $1.0B | $45.3M | ||
| Q1 25 | $1.0B | $56.7M | ||
| Q4 24 | $1.1B | $68.0M | ||
| Q3 24 | $1.1B | $79.3M | ||
| Q2 24 | $1.2B | $90.7M |
股东权益CRCPBYI
| Q1 26 | $2.9B | — | ||
| Q4 25 | $3.7B | $130.3M | ||
| Q3 25 | $3.4B | $115.3M | ||
| Q2 25 | $3.4B | $104.7M | ||
| Q1 25 | $3.5B | $97.1M | ||
| Q4 24 | $3.5B | $92.1M | ||
| Q3 24 | $3.5B | $71.1M | ||
| Q2 24 | $2.1B | $48.5M |
总资产CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | $7.4B | $216.3M | ||
| Q3 25 | $6.8B | $202.9M | ||
| Q2 25 | $6.7B | $194.9M | ||
| Q1 25 | $6.8B | $196.2M | ||
| Q4 24 | $7.1B | $213.3M | ||
| Q3 24 | $7.1B | $220.7M | ||
| Q2 24 | $4.5B | $205.0M |
负债/权益比CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | 0.29× | 0.30× | ||
| Q2 25 | 0.30× | 0.43× | ||
| Q1 25 | 0.29× | 0.58× | ||
| Q4 24 | 0.32× | 0.74× | ||
| Q3 24 | 0.32× | 1.12× | ||
| Q2 24 | 0.57× | 1.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.0M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-32.0M | $14.4M |
| 自由现金流率自由现金流/营收 | -26.9% | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $380.0M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CRCPBYI
| Q1 26 | $99.0M | — | ||
| Q4 25 | $235.0M | $14.4M | ||
| Q3 25 | $279.0M | $9.7M | ||
| Q2 25 | $165.0M | $14.1M | ||
| Q1 25 | $186.0M | $3.6M | ||
| Q4 24 | $206.0M | $15.6M | ||
| Q3 24 | $220.0M | $11.0M | ||
| Q2 24 | $97.0M | $1.0M |
自由现金流CRCPBYI
| Q1 26 | $-32.0M | — | ||
| Q4 25 | $115.0M | $14.4M | ||
| Q3 25 | $188.0M | $9.7M | ||
| Q2 25 | $109.0M | $14.1M | ||
| Q1 25 | $131.0M | $3.6M | ||
| Q4 24 | $118.0M | $15.6M | ||
| Q3 24 | $141.0M | $11.0M | ||
| Q2 24 | $63.0M | $1.0M |
自由现金流率CRCPBYI
| Q1 26 | -26.9% | — | ||
| Q4 25 | 16.9% | 19.1% | ||
| Q3 25 | 26.3% | 17.7% | ||
| Q2 25 | 15.5% | 26.8% | ||
| Q1 25 | 16.1% | 7.7% | ||
| Q4 24 | 14.3% | 26.4% | ||
| Q3 24 | 16.2% | 13.7% | ||
| Q2 24 | 15.3% | 2.1% |
资本支出强度CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | 17.7% | 0.0% | ||
| Q3 25 | 12.7% | 0.0% | ||
| Q2 25 | 8.0% | 0.0% | ||
| Q1 25 | 6.8% | 0.1% | ||
| Q4 24 | 10.7% | 0.0% | ||
| Q3 24 | 9.1% | 0.0% | ||
| Q2 24 | 8.3% | 0.0% |
现金转化率CRCPBYI
| Q1 26 | — | — | ||
| Q4 25 | 19.58× | — | ||
| Q3 25 | 4.36× | 1.10× | ||
| Q2 25 | 0.96× | 2.41× | ||
| Q1 25 | 1.62× | 1.21× | ||
| Q4 24 | 6.24× | — | ||
| Q3 24 | 0.64× | 0.54× | ||
| Q2 24 | 12.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
